Hamburg and Aachen / DE, 29. March 2017 - Logistics provider Kuehne + Nagel and pharmaceutical research company Grünenthal agree global partnership for land, air and seafreight. Kuehne + Nagel is supporting the Grünenthal Group with the reorganisation of the world-wide transportation network for highly sensitive pharmaceutical products.
Grünenthal, an international research-based pharmaceutical company headquartered in Aachen, has production sites in Europe and Latin America and through its subsidiaries is represented in 32 countries. Grünenthal products are available in 155 countries. In order to supply all its sites, Grünenthal needs a partner operating on a global scale who meets the company's extremely high demands in terms of reliability and traceability of the delivery and complies with the highest international standards. Kuehne + Nagel and Grünenthal are working together to develop a solution that is tailored to the requirements of the Grünenthal Group with KN PharmaChain as its core element. KN PharmaChain is a multi-modal logistics solution for temperature-controlled door-to-door transportation which allows accurate traceability of the deliveries and intensive, proactive risk management. Kuehne + Nagel recently became the first logistics provider worldwide to receive the IATA CEIV Pharma certification for the KN PharmaChain network covering 86 locations. The certification helps ensure the integrity of pharmaceutical products throughout the entire airfreight supply chain.
"With this new agreement, we were able to combine all our global forwarding services with the Kuehne + Nagel Group. This centralisation and our partner's expertise in the pharmaceutical industry will help us to make our processes more efficient and enhance our competitiveness", Victor Barbosa, Senior Vice President Global Supply Chain, Grünenthal, explained.
“We are delighted with the confidence the Grünenthal Group has placed in us and look forward to future collaboration. Our aim is to reshape the entire network for logistics services together with the customer. To achieve this, we will utilise our expertise in providing services for the pharmaceutical and healthcare industry, which is of strategic importance for Kuehne + Nagel”, Dr. Hansjörg Rodi, Managing Director, Kuehne + Nagel Germany, states.
In addition to the conceptual development of the network, the agreement involves integrated logistics services such as network and stock management and the global transportation of temperature-controlled products by sea, air and land.
About Kuehne + Nagel
Kuehne + Nagel is one of the world's leading logistics providers with over 70,000 employees in more than 1,300 locations in over 100 countries. Specialist areas are sea and airfreight, contract logistics and overland business, with a clear focus on areas offering high added value such as IT-based integrated logistics solutions.
For more information, visit www.kuehne-nagel.com.
The Grünenthal Group is an independent, family-owned, international research-based pharmaceutical company headquartered in Aachen, Germany. We are an entrepreneurial specialist delivering true benefits to patients. By sustainably investing in research and development above the industrial average, we are committing to innovation in order to treat unmet medical needs and bring value-adding products to markets. Grünenthal is a fully integrated research & development company with a long track record of bringing innovative pain treatments and state-of-theart technologies to patients. Altogether, the Grünenthal Group is present in 32 countries with affiliates in Europe, Latin America and the US. Grünenthal products are sold in more than 155 countries and approx. 5,500 employees are working for the Grünenthal Group worldwide. In 2016, Grünenthal achieved revenues of € 1.4 bn.
More information: www.grunenthal.com.
Head Corporate Communications
Phone +49 241 569-1568